Analyst Report
Pitt Street Research – Research Update: Advancing Invion’s Clinical Programs
Pitt Street Research – Initiation coverage 24 Aug 2023
Video Interviews
Prof Ramsay from the Peter MacCallum Cancer Centre explains the significance of his recent successful study using INV043 in combination with an immune checkpoint inhibitor (ICI) on anal cancer in mice. The study showed the use of this combination therapy resulted in ~80% of mice being tumour-free. In contrast and despite widespread use of ICIs, the patient response rate to standalone ICI therapy can be as low as 12.5%.
The 3rd Proof-of-Concept study points to an additional commercialisation pathway for INV043. Dr Andrew Stephens explains the significance of the study on using INV043 with Checkpoint Inhibitors in Combination Therapy.
The second Proof-of-Concept study using INV043 API undertaken in October 2021 produced an unexpected result, according to Dr Andrew Stephens from Hudson Institute.
Video interview with Dr Andrew Stephens from Hudson Institute who explained why he’s excited about the Proof-of-Concept findings on Invion’s INV043 API and how the unique technology could be a new way to treat a range of cancers